Asset Management for Pharmaceutical

Most of it, yes. Asset Management measurements at RAV, lifecycle cost, criticality scores are non-intrusive — readings happen at the bearing housing or terminal box without interrupting the equipment. The exceptions are deep diagnostic work that requires de-energization or process isolation, which most Reliability Consulting for Pharmaceutical Manufacturing facilities batch into existing maintenance windows. Routine Asset Management rounds disrupt nothing.

Top 30 assets ranked by failure consequence, three months of baseline data, then expand based on what the data shows. Trying to cover the full Reliability Consulting for Pharmaceutical Manufacturing equipment population in month one creates noisy data nobody trusts. Tight scope with deep work establishes credibility — that's what gets the budget approved for broader coverage at month four or five.

Pharmaceutical operations bring three things to the Asset Management program that aren't there in general industry. The operating environment is harder (GMP validation, cleanroom equipment, batch traceability). The regulatory framework adds documentation requirements (FDA cGMP, EU Annex 15, ICH Q7). And the cost of failure is higher — typical unplanned downtime runs $10K-$80K/hour with batch loss risk. A Asset Management program built for Pharmaceutical accounts for all three: tighter intervals on the equipment most exposed to sanitary pump reliability, clean utility integrity, batch traceability, audit-ready reporting templates, and faster response times on flagged developing faults.

Most of it, yes. Asset Management measurements at RAV, lifecycle cost, criticality scores are non-intrusive — readings happen at the bearing housing or terminal box without interrupting the equipment. The exceptions are deep diagnostic work that requires de-energization or process isolation, which most Pharmaceutical facilities batch into existing maintenance windows. Routine Asset Management rounds disrupt nothing.